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Abstract
Diffusion-weighted magnetic resonance imaging (MRI) provides unparalleled information and
measurements of lung structure and function without the burden of ionizing radiation. In
particular, diffusion-weighted MRI provides estimates of airspace enlargement, which is a
hallmark characteristic of emphysema. MRI provides a way to measure in vivo mean-linearintercept (Lm) and this is a promising measurement for clinical evaluation of disease
progression in patients with Alpha-1 Antitrypsin Deficiency (AATD) in which airspace
enlargement begins early in life. As such, our objective was to evaluate MRI measurements
of airspace enlargement in AATD patients and compare these measurements to ex-smokers
with chronic obstructive pulmonary disease (COPD) and healthy never-smokers.

We

compared these measurements with standard clinical measurements provided by spirometry,
plethysmography and computed tomography; we also demonstrated that MRI detected
differences in disease severity in patients with clinically similar measurements.
(135/150 words)
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INTRODUCTION

“Can one hear the shape of a drum?” - Mark Kac.1 This simple question builds the
foundation for this research. Can you listen to an MRI signal from the lung parenchyma
and from that determine its shape and form? This introduction provides the required
information as a prelude to the remaining chapters which explore this question across a
range of lung disease.

Motivation and Rationale
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and
hospitalizations worldwide.2 It affects millions of people and has an incredible economic
burden on the healthcare system in Canada.3 The hallmark features of COPD include
thickening of the bronchial walls, excessive mucus production and partial or complete
destruction of the alveolar ducts and sacs.4 This combination of factors leads to a decrease
in pulmonary function and overall quality of life. Individuals with a diagnosis of Alpha-1
Antitrypsin Deficiency (AATD) lack a protein required for regulation of neutrophil elastase
and as a result can rapidly develop a phenotype of COPD called emphysema. 5
Unfortunately, there is no cure for AATD and current treatment is expensive,6 and has
controversial efficacy with no improvements in exercise capacity or quality of life for the
patient.7 Emphysema is characterized by parenchymal destruction which results in overall
airspace enlargement. This enlargement can be characterized by lung morphometry, the
study of lung form. This can be used to quantify disease severity and progression
regionally throughout the lung. The American Thoracic Society (ATS) and European
Respiratory Society (ERS) joint task force consider quantification of lung structure to be
the gold standard in evaluating clinical interventions, severity of disease and response to
treatment.8
In the clinic, measurements of lung structure and function are made using a wide range of
tools, from simple airflow measurements to complex three dimensional computed
tomography (CT). Many of these tools will be outlined in further detail later in this chapter.
Airflow measurements (spirometry) taken at the mouth can be used to quantify lung
1

function and airflow obstruction. Spirometry is the gold standard for diagnosis of chronic
obstructive pulmonary disease. It is also possible to measure lung volumes which can give
the volume of gas remaining in the lungs after full exhalation. The volume remaining at
the end of exhalation (RV) as a ratio of total lung capacity (TLC) is a measurement of gas
trapping. Diffusion tests can give an estimate of the ability for O2 to diffuse across the
alveolar-capillary membrane which is a quantity that is reduced in diseases such as
emphysema. Measurements of lung structure and form can be performed using imaging
techniques such as planar x-rays or by extending this to 3D x-ray CT. These techniques
allow measurements of lung volumes and tissue density to be made but to truly measure
the structure and form of the lung and the lung parenchyma, novel morphometry techniques
must be employed to obtain measurements such as the surface-to-volume ratio and mean
cord length.
Lung morphometry is not a new field. However, until recently, it relied on histology to
provide 2D cross sections with which the overall 3D structure of the lungs are estimated.9,10
In this method, an excised lung or section of the lung is sliced into 2D cross sections and
through point counting, intersection counting and transect counting an estimation of lung
volume, surface area or mean cord length can be made.9 Unfortunately, this method relies
on excised lung tissue thus limiting it to ex-vivo analysis.
Unfortunately, there are limited methods that provide accurate measurements of airspace
size in vivo. Hyperpolarized noble-gas magnetic resonance imaging (MRI) provides an
ionizing radiation free method of quantifying lung structure function in vivo.

To

accomplish this, diffusion-weighted MRI is employed, which measures the self-diffusion
of the noble-gas molecules within the confinement of the lung parenchyma. Since the
noble-gases used are biologically inert, this diffusion is related to the confining geometry,
in this case that of the lung parenchyma. There has been much work done in measuring
this confinement in the form of an apparent diffusion coefficient (ADC). Previous work in
AATD measuring ADC,11-14 relied on the single diffusion-weighted approach and did not
extend to multiple diffusion-weights which can provide a more sensitive measurement of
geometry. Recent work however, looked at a population of AATD subjects using different
multiple diffusion-weighted modelling approaches but did so only for a single centre
2

coronal slice and without comparison to standard clinical measurements or regional
evaluation.15
This thesis focuses on evaluation of alveolar destruction in COPD and AATD using
multiple diffusion-weights, comparing these measurements to those used clinically such as
spirometry and computed tomography as well as evaluating measurements of airspace
enlargement regionally throughout the lung.
This thesis chapter will provide prerequisite knowledge to understand the original research
presented in Chapter 2.

Lung Structure and Function
The primary function of the lungs is gas exchange. The lungs consist of branching
generations (Figure 1-1) of bronchioles which ultimately end in the alveoli, where the
majority of gas exchange occurs. The lungs can be divided into two sections, the
conducting zone and the respiratory zone.

1.2.1

Conducting Zone

Beginning at the nose, the conducting zone is the first portion of the respiratory tract. This
portion of the airways consists of those with the largest diameter with the main purpose of
filtration, warming and transportation of incoming air. The conducting zone concludes at
the terminal bronchioles.

In the respiratory tract, the conducting zone consists of

generations 1 to 16.

1.2.2

Respiratory Zone

The respiratory zone, generations 17 until the alveoli is the site of gas exchange in the
lungs. This is the portion of the respiratory tract with the largest surface area which makes
up the bulk of the lung parenchyma. This region of the lung consists primarily of the
alveolar ducts, sacs and the alveoli. The alveoli are responsible for 90% of the gas
exchange whereas the preceding respiratory bronchioles and alveolar ducts account for
only 10%.

3

Figure 1-1: Conducting and Respiratory Zones
Respiratory tract generations (Z) with both conducting and respiratory zones beginning at
the trachea (Z = 0) and ending at the alveoli (Z = 23). Adapted from West, JB, Respiratory
Physiology: The Essentials, Ninth Edition.16

1.2.3

The Alveoli

The alveoli comprise the bulk of the lung parenchyma as they line the walls of the airways
in the respiratory zone. Each alveolus is approximately 330 um in diameter16 and the
average adult has 480 million alveoli.17 As a result of their small diameter and the vast
number of alveoli, they have a surface area of roughly 70 m2.18 This is the hallmark feature
of the efficient lung, as the total surface area influences its ability to receive deoxygenated
blood and inversely supply the heart with oxygen during respiration. Any disease which
results in destruction to the alveoli will ultimately reduce the surface area available for gas
exchange and in turn result in a reduction of pulmonary function and quality of life for the
individual.
4

Chronic Obstructive Pulmonary Disease
Having classically been defined as consisting of two distinct, but intertwined, phenotypes
COPD is a progressive disease leading to airflow limitations and reduced quality of life. A
patient with chronic bronchitis, often referred to as a “blue bloater”, can be visualized as a
person with a larger stocky build and a history of a chronic cough.4 A patient with
emphysema, often referred to as a “pink puffer”, will be someone with recent weight loss
and abnormal physical weakness.4 The current diagnostic criteria for COPD are outlined
by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.19 The
GOLD severity grades are provided in Table 1-1 where FEV1 is an airflow measurement
taken using a spirometer explained in more detail in Section 1.5.1.
Table 1-1: GOLD Severity Grades
Patient with FEV1/FVC < 70%
GOLD I

Mild

FEV1 ≥ 80%pred

GOLD II

Moderate

50% ≤ FEV1 < 80%pred

GOLD III

Severe

30% ≤ FEV1 < 50%pred

GOLD IV

Very Severe

FEV1 < 30%pred

FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity

1.3.1

Chronic Bronchitis

Chronic bronchitis is inflammation of the bronchial tubes, primarily in the mucus glands.4
This inflammation results in an over-production of mucus by the goblet cells which are
located on the epithelial lining of the respiratory tracts.20 The combination of mucus lining
the bronchial tubes and the inflammation results in airflow limitations. The primary cause
of chronic bronchitis is cigarette smoking, but that is not the only cause.4,21
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1.3.2

Emphysema

Emphysema affects the airspace distal to the terminal bronchioles. It is characterized by
the destruction of the walls of the alveolar ducts, sacs, or both.4 It is a result of an imbalance
of proteases due to either an increased production of proteases or reduced production of
antiproteases.22

There are two main types of recognized emphysema (Figure 1-2):

Centriacinar emphysema, where destruction is limited to the central lobule leaving the
alveolar ducts and sacs unharmed and panacinar emphysema where destruction occurs
across the entire lobule.

Figure 1-2: Centriacinar and Panacinar Emphysema
Normal respiratory bronchioles, respiratory bronchioles affected by centriacinar
emphysema where the emphysema is confined the terminal and respiratory bronchioles
(TB and RB). This destruction is extended to the alveoli (A) in panacinar emphysema.
Adapted from West, JB, Pulmonary Pathophysiology: The Essentials, 4th Edition.4
The destruction of the lung parenchyma can be seen in Figure 1-3 showing micro-CT
images of a healthy young subject, healthy elderly subject and an ex-smoker. All three
images have the same field of view (FOV) = 40mm.
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Figure 1-3: Micro-CT Lung Images
Micro-CT images showing a healthy young lung with tightly packed alveoli, a healthy old
lung23 showing gradual enlargement of the lung parenchyma and an ex-smoker lung23
showing emphysematous destruction of the lung parenchyma. (Healthy young lung
courtesy of Dr. Vasilescu and Dr. Hogg (UBC)). Healthy Old Lung and Ex-Smoker Lung
reproduced with permission (Appendix A).
Emphysema is most frequently encountered in the proximal respiratory bronchioles in the
upper lobes.24,25 This is referred to as centrilobular emphysema and is primarily associated
with smoking related emphysema. Emphysema can also be located distal to the respiratory
bronchioles localized in the basal portion of the lung. This pattern of emphysema is referred
to as panlobular emphysema and is characteristic of, but not limited to, AATD related
emphysema.26

Alpha-1 Antitrypsin Deficiency
1.4.1

Biology

AATD was first described in 1963 by Laurell and Eriksson.27 AATD is an underdiagnosed
genetic condition affecting up to 1 in 1500 people of European descent.6,28 It causes
mutations in the SERPINA1 gene which contains instructions for producing a protein
called alpha-1 antitrypsin. This protein protects the body from neutrophil elastase, which
is released from white blood cells in response to infection but will attack healthy tissue if
not regulated.29,30 The normal allele of the SERPINA1 gene, M, results in normal levels
of alpha-1 antitrypsin. Two other variants the S and Z variants produce decreasing amounts
of alpha-1 antitrypsin.31 There are over 100 different alleles worldwide.32
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1.4.2

Liver Disease

Approximately 15% of all alpha-1 antitrypsin deficiency sufferers will develop liver
disease.33 As the alpha-1 antitrypsin is not secreted properly34 (as a result of protein misfolding) it accumulates in the liver and can cause liver cirrhosis, an accumulation of liver
scar tissue.35

1.4.3

Lung Disease

AATD primarily manifests in the form of panlobular emphysema. The imbalance of
neutrophil elastase will result in destruction of connective tissue within the lungs and a
breakdown of the alveoli leading to reduced surface area and in turn diminishing the lungs’
capacity for gas exchange. Emphysema as a result of AATD predominately affects the
basal portion (~64% of patients)36 of the lung due to the gravitational dependence of
pulmonary blood flow. This is not always the case and upper lobular emphysema can also
occur as can other respiratory disorders such as bronchiectasis.37

1.4.4

Augmentation Therapy

At this time there is no cure for AATD and current treatment is geared solely towards
symptomatic relief.32 Intravenous supplementation of exogenous alpha-1 antitrypsin has
been shown to both slow the decline of the forced expiratory volume in 1 second (FEV1)
in patients with AATD38,39 and slow the decline in lung tissue density as measured by xray computed tomography.7 Augmentation therapy is a costly procedure and there are
some debates on who would benefit the most from treatment.40 In addition, recent clinical
trials have not shown significant changes in exercise capacity, patient perceived quality of
life, exacerbations or hospitalizations as a result of treatment.7 To overcome this, there is
preliminary work examining novel treatments for AATD emphysema including gene
therapy41-44 and pluripotent stem cells.45,46 In order to accurately gauge the efficacy of
these novel treatments, pulmonary imaging must be employed as it has previously played
an important role in demonstrating treatment efficacy with respect to lung density changes.
However, to truly measure airspace enlargement in vivo lung morphometry techniques,
which can give measures of airspace enlargement and surface-to-volume ratios, are
required. These measurements must be sufficiently sensitive to detect small changes in
8

early and mild disease as well as severe end stage emphysema. If a sensitive measurement
of disease and airspace enlargement were developed and applied to clinical efficacy
evaluation of novel treatments it would be possible to perform smaller single-centre
studies. This would result in a drastic reduction in costs and ultimately aid in the
development of novel treatments of AATD emphysema.

Clinical Measurements of Lung Disease
1.5.1

Spirometry

Worldwide, spirometry provides the gold standard measurement for the diagnosis and
clinical evaluation of COPD.19 Spirometry tests by patients who are coached by a trained
pulmonary technologist for which there are accepted guidelines on reproducibility and
evaluation.47 Spirometry measurements are inexpensive and reproducible while requiring
little specialized equipment or training; however, they rely solely on airflow measurements
taken at the mouth and therefore provide a single global measurement representing lung
function.47 This unfortunately fails to unmask the many faces of COPD and hides its
underlying heterogeneity.48,49 The primary measurement of airflow limitation is the FEV1
which is a measurement of the maximum amount of air exhaled during the first 1 second
of a forced expiration. Figure 1-4 shows a sample flow volume curve for a normal healthy
individual (Figure 1-4A) and a flow volume curve for someone with an obstructive lung
disease (Figure 1-4B). The total volume of air exhaled during this breathing maneuver is
the forced vital capacity (FVC).
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Figure 1-4: Flow Volume Curve
Sample flow volume curves for a healthy (A) patient and someone with obstructive lung
disease (B). In obstructive lung disease, flow rates are slower resulting in a lower FEV1.

1.5.2

Lung Volumes and Capacities

In addition to FEV1 and FVC it is possible to measure patient lung volumes using a
plethysmograph. Briefly, a plethysmograph is a closed system in which the patient sits that
is used to measure lung volumes, specifically the functional residual capacity (FRC), total
lung capacity (TLC) and the residual volume (RV). FRC is the volume of air in the lungs
remaining at the end of a passive expiration during a normal breathing cycle and RV is the
volume of air in the lungs remaining at the end of a full expiration. To accomplish this
Boyles law is implemented and using measured pressure differences one can derive the
aforementioned lung volumes.50
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Figure 1-5: Lung Volumes
A volume time curve showing clinically relevant lung volumes. Relevant lung volumes
for this work are: Residual Volume (RV), the volume remaining after full expiration;
Functional Residual Capacity (FRC), the volume remaining after passive expiration and
Total Lung Capacity (TLC); the total lung volume after a full inspiration.
The measurement of TLC and RV/TLC is important as it represents hyperinflation of the
lungs which is a hallmark sign of COPD due to either the loss of the elastic property of the
lung parenchyma or an obstruction in the passage of air.

1.5.3

Diffusing Capacity of the Lung for Carbon Monoxide

The diffusing capacity of the lung for carbon monoxide (DLCO) test measures the amount
of oxygen passing from the alveolar sacs into the blood. During the test the patient breathes
in a test gas containing a small amount of tracer gas (CO) and holds their breath.51 CO is
used due to its affinity to bind to hemoglobin, making the uptake of CO diffusion limited
as opposed to perfusion limited. This means that the amount of gas taken up is solely
dependent on diffusion and not the amount of available blood flow.4 Upon a breath-hold
of 10 seconds the patient exhales and the exhaled gas is tested to determine the amount of
tracer gas that was absorbed during the duration of the breath hold.51 This test is especially
important in patients with emphysema as the destruction of the alveolar sacs leads to a
decreased capacity for gas exchange between the air sacs and blood. A measurement of
DLCO normalized to the alveolar volume (DLCO/VA) has been proposed as a more specific
11

measurement.52,53 Although simple and quick, this tests lacks reproducibility over time54
and therefore may be unattractive in cases where longitudinal monitoring may be required.
A low DLCO combined with an increase in TLC, RV/TLC is a classic sign of emphysema
as observed by pulmonary function testing.55

1.5.4

Six-Minute Walk Test

Patient exercise capacity can be measured by performing the six-minute walk test (6MWT).
In the 6MWT the patient walks at a self-set pace, resting as necessary, on a flat surface for
six minutes. The six minute walk test does not provide specific information of the limiting
exercise factor but is reflective of the activities performed during day to day life. Before
and after performing the six minute walk test the patient answers two questions on
perceived levels of exhaustion56 and has measurements of arterial oxygenation (SPO2) and
heart rate taken. All six minute walk tests performed for this thesis are to American
Thoracic Society guidelines.57,58

1.5.5

St. George’s Respiratory Questionnaire

The St. George’s Respiratory Questionnaire (SGRQ)59 is designed to measure the overall
impact that respiratory disease has on the quality of life as perceived by the patient. There
are two sections a symptoms section and an activities section which relate to the symptoms
experienced and the burden of the disease. The questionnaire is scored from 0 to 100 with
higher scores indicating worse perceived quality of life and symptoms.

X-Ray Computed Tomography
1.6.1

Theory

At its most basic level, x-ray computed tomography (CT) is an extension of planar x-ray
imaging to three dimensions using a rotating x-ray tube and detector combined with a
motorized patient bed.60 The contrast in the image is related to the radiodensity of the
scanned material where each value represents a Hounsfield unit (HU) corresponding to:
𝐻𝑈 = 1000 ∗

𝜇 − 𝜇𝑤𝑎𝑡𝑒𝑟
𝜇𝑤𝑎𝑡𝑒𝑟 − 𝜇𝑎𝑖𝑟
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(1-1)

With 𝜇 being the linear attenuation coefficient and 0 HU being defined as the radiodensity
of distilled water at standard pressure and temperature.

1.6.2

Pulmonary X-Ray Computed Tomography

CT imaging of the lung can be used to visualize regions of low attenuation and quantify
both gas trapping and emphysema. Typical lung parenchyma attenuation values are
between -910 and -500 HU.61 A CT scan performed at full expiration can be used to
quantify regions of gas trapping which are regions where gas is not cleared through
exhalation. To do so the regions of the lung <-856 HU are examined.62 A full inspiration
CT can be used to quantify regions of emphysema. Using the attenuation <-950 HU as an
emphysema threshold.63 This can be quantified using the relative area of the CT density
histogram with values <-950 HU (RA950). RA950 measurements correlate well with
radiologist scores,64 histology65 and pulmonary function testing.66 Regions of the CT lung
density histogram representing airspace enlargement are shown in Figure 1-6 for a healthy
never-smoker and representative AATD subject. Combining inspiration and expiration CT
scans together, a regional map of gas trapping and emphysema can be made.67 This
method, called parametric response mapping, co-registers the inspiratory and expiratory
CT scans and generates a lung map showing regions of gas trapping and emphysema.
These methods can provide regional information of emphysema and gas trapping
throughout the lung. In addition to quantifying regions of emphysema and gas trapping
CT provides a measurement of lung density (g/L).68,69 Unfortunately, current spatial
resolutions available with CT are not fine enough to visualize the smaller airways. There
are other quantification methods such as examining low attenuating clusters (LAC)70 where
the cumulative size distribution of these low attenuating clusters (<-950 HU) are described
by a power law relationship with the number of low attenuating clusters. This in principle
relates the size of these emphysematous lesions and the number of lesions using CT. This
can be graphically illustrated as low attenuating spheres where the size of the sphere is
proportional to the cumulative lesion size.
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Figure 1-6: CT Radiodensity and Histogram
CT images with yellow masks corresponding to voxels <-950 HU and the corresponding
whole lung CT radiodensity histogram for a healthy never-smoker and subject with
AATD
Since the development of micro-CT spatial resolutions approaching 4 µm may be
obtained.71 Micro-CT as a method of visualizing and quantifying lung morphometry has
been thoroughly demonstrated in mice,72 pigs73 and cadaveric human lung specimens,23,71
including AATD donor lungs;74 however, the scan speed and radiation exposure required
to execute a scan leaves the feasibility of micro-CT geared solely to ex-vivo imaging.75,76

Magnetic Resonance Imaging
1.7.1

Theory

Conventional 1H MRI of the body is possible due to the high concentration of 1H molecules
comprising various biological tissues. The gyromagnetic ratio (γ) of a nucleus will in part
determine the MR signal. The high γ of 1H (γ1H = 42.6 MHz T-1) combined with the natural
abundance of 1H located inside biological tissue provides ample signal for imaging most
14

of the body. Unfortunately, the lungs have incredibly low density (133g/L - 200g/L)77 and
have millions of air tissue interfaces which result in magnetic field inhomogeneities within
the lung parenchyma. This makes clinically available 1H MRI unsuitable for quantitative
evaluation of the lung or the diseases which affect it.

1.7.2

Pulmonary Magnetic Resonance Imaging

Conventional 1H MRI of the lungs is difficult due to the high concentration of air contained
within the lungs, and consequently the low tissue density.77

This is made further

complicated by the large number of air-tissue interfaces which affect magnetic field
homogeneity within the lungs. For these reasons, the lungs appear as dark voids (Figure
1-7) providing little to no information on lung structure-function.

Figure 1-7: 1H Thorax image for representative NS, COPD and AATD Subjects
This limitation can be circumvented by using multinuclear MRI and as opposed to
measuring 1H density, one measures the relative density of an inhaled hyperpolarized
noble-gas. Through spin-exchange optical pumping, noble-gases can be hyperpolarized
and used for imaging of the lungs after inhalation.78 This is important because the MRI
signal is proportional, to the following factors:79
1
𝑆 ∝ 𝑁|𝛾|ℏ𝜔0 𝑃𝑁
2

(1-2)

Where S is the MRI signal, N is the number of spins, γ is the gyromagnetic ratio, ℏ is the
reduced Plank constant, 𝜔0 is the Larmor frequency and PN is the nuclear polarization. In
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the case of 1H MRI the high N provides adequate signal for imaging purposes; however,
in the case of hyperpolarized noble-gas imaging thermally polarized noble-gas to provides
inadequate signal due to the small N and PN. However, this can be overcome by raising
the PN through external polarization of the noble-gas. This technique allows visualization
of gas dispersion within the lungs.

1.7.2.1

1

H Methods

There are however methods utilizing traditional 1H imaging which provide information
suitable for quantitative image analysis. These methods are currently under investigation
in research settings but may serve to provide translatable lung imaging. Two methods are
Fourier decomposition (FD) MRI80 and Ultrashort Echo Time (UTE) MRI.81

1.7.2.1.1

Fourier Decomposition

During a period of free breathing, multiple images are taken of a single slice through the
lungs. The images are then deformably registered82 to each other to account for cardiac
motion and the varying lung volumes throughout the respiratory cycle. The discrete
Fourier transform is taken at each lung voxel and ventilation and perfusion maps can be
obtained by observing the corresponding peak at either the respiratory rate (ventilation) or
cardiac rate (perfusion). Ventilation maps obtained from FD MRI have been shown to
correlate with ventilation maps obtained from 3He.83

1.7.2.1.2

Ultrashort Echo Time

To overcome the difficulties in lung imaging a method using echo times (TE) of ~50us and
3D radial k-space trajectories has been developed. MRI is performed at four lung volumes:
full expiration, FRC, FRC+1L and full inhalation. Absolute signal intensity is normalized
to the liver and dynamic proton maps (registered to FRC+1L) can be computed using the
lung volumes. The UTE signal has been shown to be related to lung volume suggesting a
relationship to tissue density.84 It is also related to gas-trapping in asthmatics.85
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1.7.2.2

Hyperpolarized Methods

1.7.2.2.1

Spin Physics and Polarization

By using spin-exchange optical pumping (SEOP) high levels of 3He or 129Xe polarization
can be achieved.79 The SEOP system uses circularly polarized resonance light which is
absorbed by rubidium housed within a glass cell. Contained within the same glass cell is
the noble-gas used in the spin-exchange, 3He in this case.

Angular momentum is

transferred through binary collisions from the polarized rubidium to the 3He. Over time as
collisions increase, this causes an increase of the 3He nuclear polarization to several orders
of magnitude larger than the thermal polarization obtained using magnetic fields. A full
theoretical description of SEOP of noble-gas nuclei can be found in a review by Walker
and Happer 1997.86

1.7.2.2.2

Static Ventilation MRI

By imaging the spin density of the polarized noble-gas during a breath-hold, visualization
of gas distribution throughout the lungs can be achieved. These images are coined static
ventilation (SV) images and as the name indicates they give a single static image of gas
distribution. This is shown in Figure 1-8, these are the same subjects and slices as Figure
7. This image, can be qualitatively analyzed by identifying regions of hypo-intense signal
(signal voids) as well as regions of hyper-intense signal. These regions can also be
quantified using semi-automated segmentation methods,87 where the 1H and 3He images
are co-registered using an affine transformation, to determine the ventilation defect percent
(VDP) which is the volume of ventilation defects (signal voids) normalized to the thoracic
cavity volume.
𝑉𝐷𝑃 [%] =

𝑉𝑒𝑛𝑡𝑖𝑙𝑎𝑡𝑖𝑜𝑛 𝑑𝑒𝑓𝑒𝑐𝑡 𝑣𝑜𝑙𝑢𝑚𝑒
𝑥 100%
𝑇ℎ𝑜𝑟𝑎𝑐𝑖𝑐 𝑐𝑎𝑣𝑖𝑡𝑦 𝑣𝑜𝑙𝑢𝑚𝑒
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(1-3)

Figure 1-8: Static ventilation images for representative NS, COPD and AATD
subjects
3
He static ventilation (cyan) overlaid on 1H thorax image for a representative subjects
VDP has been shown to correlate with aging,88 ventilation homogeneity,89 and
spirometry.90 VDP shows response to bronchodilation in asthmatics,91 as well as response
to bronchoconstriction (methacholine).92

1.7.2.2.3

Diffusion-weighted MRI

Using a similar method to what is used to acquire SV images, and employing a diffusionweighted pulse sequence93 (Figure 1-9) diffusion-weighted images can be acquired. Due
to the loss of the MR signal at high b-values, the highest b-values are acquired first to
maximize the signal at those values. The diffusion gradient is shown in blue for interleaves
2-5. These images allow visualization and quantification of the extent to which the noblegas molecules are able to diffuse within the confining space of the alveolus.94
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Figure 1-9: Diffusion-weighted Pulse Sequence
A multiple b-value fast gradient recalled echo (FGRE) pulse sequence. Interleave 1
acquires a non-diffusion-weighted static ventilation image and interleaves 2-5 acquire
diffusion weighted images due to the diffusion gradient (in blue). The size and strength of
the diffusion gradient are varied to acquire multiple b-values.

1.7.2.2.4

Apparent Diffusion Coefficient

In a confined medium, such as an airway or alveolus, the root mean square displacement
(<r2>) of a noble-gas molecule and its diffusion time (t) can be related to an apparent
diffusion coefficient (ADC) giving a relative measure of confinement:

𝐴𝐷𝐶 =

< 𝑟2 >
2𝑡

(1-4)

Diffusion-weighted MRI can extract this ADC through diffusion-weighted pulse sequences
(Figure 1-9). First, a non-diffusion-weighted (static ventilation) image is acquired as
described in Section 1.7.2.2.2, and for the same slice a second, diffusion-weighted, image
𝑠

is acquired. For this image, the so-called b-value [𝑐𝑚2 ] indicates the size and strength of
this diffusion gradient (Figure 1-10).
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Figure 1-10: Diffusion sensitizing pulse gradient waveform
A bipolar trapezoidal diffusion sensitizing gradient. Gm = maximum gradient amplitude, 𝜏
= gradient ramp up/down time, 𝛿 = lobe duration, ∆ = diffusion time.
𝛿
7
8 2
𝑏 = (𝛾𝐺𝑚 )2 [𝛿 2 (∆ − ) + 𝜏 (𝛿 2 − 2∆𝛿 + ∆𝜏 − 𝛿𝜏 +
𝜏 )]
3
6
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(1-5)

With 𝛾 = gyromagnetic ratio, Gm = maximum gradient, 𝜏 = gradient ramp up/down time,
𝛿 = lobe duration and ∆ = diffusion time. The b-value is chosen based on the confining
medium and the free diffusion of the noble-gas used. A good rule of thumb for b-value
selection is (𝑏 ∙ 𝐴𝐷𝐶) ≅ 1.95 This bipolar diffusion gradient works by dephasing the
nuclear spins,93 this effectively encodes the initial position of the nuclei. The negative
portion of the gradient will rephrase the spins but it will not completely rephrase them as
diffusion has occurred.

Thus, by relating the relative signal intensities in both the

diffusion-weighted and non-diffusion-weighted images the ADC can be measured as
shown in equation 1-7:
𝑆(𝑏)
= exp(−𝑏 ∙ 𝐴𝐷𝐶)
𝑆0
ln(
𝐴𝐷𝐶(𝑏) =

𝑆0
)
𝑆(𝑏)
𝑏

(1-6)

(1-7)

Where commonly used b-values for lung imaging range between 1.6 and 6.4 s/cm2 for 3He
and 12 and 30 s/cm2 for 129Xe. Figure 1-11 shows diffusion and non-diffusion-weighted
3

He ventilation images for the same slice in a subject with AATD.
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Figure 1-11: Non-Diffusion and Diffusion-weighted 3He Ventilation Image
When Equation 1-7 is applied to each voxel, a map of ADC can be generated. Figure 112, shows the ADC map generated from the images in Figure 1-11.

Figure 1-12: Static ventilation and ADC for AATD subject
Static ventilation and slice matched ADC image for a representative AATD subject.
Female, 58 years old. FEV1 = 32%pred, FEV1/FVC = 31%, RV/TLC = 62%, DLCO = 53
%pred, ADC = 0.43 cm2/s.
3

He ADC has been shown to correlate well with patient measurements of disease,94

histological measurements of Lm96 and CT measurements of emphysema.97 It is elevated
in asthmatics post methacholine challenge, representing gas trapping.92 ADC is also related
to lung inflation levels98 as well as patient age.99,100 There has been a large body of work
21

performed using 3He, there have been preliminary reports of

129

Xe ADC in healthy

volunteers and subjects with COPD101-103 with 129Xe ADC measurements correlating with
histological measurements.104

1.7.2.2.5

Multiple b-value ADC Magnetic Resonance Imaging

By varying the b-values used, a set of multiple b-value images can be acquired for the same
slice. During an acquisition a molecule will either experience free unrestricted diffusion,
or it will experience restricted diffusion due to the presence of airspace walls. At different
b-values varying number of molecules will experience restriction due to the presence of
the airspace walls. This technique can be used to probe varying length scales. Using the
signal decay as a function of b-value measures a voxel-wise mean of airspace sizes. This
technique provides a more sensitive measurement, as compared to two b-value ADC
measurements, of alveolar size

1.7.2.3

Measurements of Alveolar Geometry using Multiple-b ADC

Measurements of alveolar geometry can be made using assumptions of the noble gas
displacement within the alveolus. The assumption made in this thesis, based on previous
work, is that the diffusion within the airways is anisotropic. A cylindrical geometry of the
alveoli and alveoli ducts is assumed.

1.7.2.3.1

Weibel Model of Alveolar Geometry

The primary geometrical representation of the acinar airways is the Weibel
representation.18 In this representation (Figure 1-13), the airway is approximated as an

22

infinite cylinder (Figure 1-14) with inner and outer radii (r and R, respectively) and 8
alveoli surrounding the cylinder with height h=R-r.

Figure 1-13: Weibel representation of the acinar duct
An acinar duct covered in a sleeve of alveoli. R = external airway radius, r = internal airway
radius, L = alveoli length, h = alveoli sheath, DL = MRI longitudinal diffusion coefficient,
DT = MRI transverse diffusion coefficient

Figure 1-14: Infinite cylinder geometry
The Weibel representation is considered as a cylindrical tube surrounded by a sleeve of
alveoli. R= external airway radius, r = internal airway radius.
The outer cylinder represents a sleeve of alveoli surrounding the alveolar duct. The
diffusion of the noble gas within the acinar airways is assumed to be anisotropic, consisting
23

of both longitudinal (DL) and transverse (DT) diffusion coefficients. The total MR signal
acquired from a single voxel is:105
1
2

𝜋

𝑆(𝑏)=𝑆0 𝑒𝑥𝑝(−𝑏𝐷𝑇 ) (4𝑏(𝐷
Where 𝛷 is the error function (𝛷(𝑥) =

𝐿 −𝐷𝑇

1

) 𝛷 [(𝑏(𝐷𝐿 − 𝐷𝑇 )2 ]
)

1 𝑥 −𝑡 2
∫ 𝑒 𝑑𝑡).
√𝜋 −𝑥

(1-8)

Using this MR signal as well as

Monte-Carlo derived equations105 for the transverse and longitudinal diffusion are used to
find geometrical expressions for the inner (r) and outer radii (R). These geometrical values
can then be used to find the alveolar length, surface-to-volume ratio and mean linear
intercept as follows:
𝜋
𝐿 = 2𝑅𝑠𝑖𝑛( )
8

(1-9)

𝑆 2𝜋𝑅𝐿 + 2𝜋(𝑅 2 − 𝑟 2 ) + 16(𝑅 − 𝑟)𝐿
=
𝑉
𝜋𝑅 2 𝐿

(1-10)

𝐿𝑚 = 4

𝑉
𝑆

(1-11)

Measurements of airspace size (Lm) measured using this geometrical model have been
shown to correlate with histology,106 show differences between elderly smokers and neversmokers107,108 as well as correlate with disease severity.

Thesis Objectives
In this thesis, my objective was to evaluate multiple b-value MRI in subjects with AATD
and examine regional MRI biomarkers of emphysema. This is important because in AATD
disease manifests at a young age and longitudinal evaluation is important both clinically
and in the process of development of novel treatments. I hypothesized that subjects with a
clinical diagnosis of AATD would show significantly elevated morphometry values as
compared to ex-smokers with COPD and age-matched healthy elderly never-smokers. I
would expect to observe these differences since in AATD disease begins from birth and as
such, would differ from smoking-related disease and that observed in senile emphysema.
24

To test this hypothesis, I performed a proof-of-concept demonstration in a small group of
subjects with AATD, subjects with smoking related emphysema and a group of healthy
age-matched never-smokers. I compared whole lung diffusion weighted measurements of
airspace enlargement across all three groups and examined these measurements regionally
throughout the lung.

These measurements were also compared to standard clinical

measurements such as spirometry and CT.
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Chapter 2: Pulmonary 3He Magnetic Resonance Imaging
Biomarkers of Emphysema in Alpha-1 Antitrypsin Deficiency

The contents of this chapter have been accepted to Academic Radiology as an original
research article authored by Eric Lessard, Heather M Young, Anurag Bhalla, Damien
Pike, Khadija Sheikh, David G McCormack, Alexei Ouriadov and Grace Parraga titled
Pulmonary 3He Magnetic Resonance Imaging Biomarkers of Regional Airspace
Enlargement in Alpha-1 Antitrypsin Deficiency. To better understand AATD related
emphysema as measured by diffusion-weighted MRI we evaluated a small group of subjects
with AATD using diffusion-weighted MRI, CT, spirometry, plethysmography and DLCO.
We compared these measurements to those obtained in ex-smokers with smoking related
emphysema and healthy age-matched never-smokers.

Introduction
Alpha-1 Antitrypsin Deficiency (AATD), first described by Laurell and Eriksson in 1963,1
is an autosomal co-dominant hereditary disorder caused by a mutation in the SERPINA1
gene, which leads to dysregulation of neutrophil elastase.2 This commonly manifests as
early-onset panlobular emphysema and affects approximately 1/5000 North Americans.2,3
Respiratory failure accounts for 45-72% of deaths in patients with AATD. Importantly, an
increased risk of mortality may be predicted using CT biomarkers of emphysema2 and
overall, outcomes are worse when patients cannot access augmentation therapy.4
As is the case for smoking-related emphysema, there is no cure for AATD, although current
AATD treatments aimed at slowing disease progression include exogenous alpha-1
antitrypsin augmentation therapy.

X-ray computed tomography (CT) lung density

measurements showed that augmentation therapy may slow the rate of emphysema
progression in AATD patients4 - an important finding that may help guide treatment
decisions given the high cost of intravenous augmentation treatment.2 However, while the
CT measurement of emphysema progression was significantly lower in the treatment arm
of the RAPID study, this did not correlate with similar changes in patient-related qualityof-life measurements.4 This important limitation is also motivating the development of
novel biomarkers and intermediate endpoints of AATD emphysema for novel treatments
including gene therapy5 and pluripotent stem cells.6,7
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The decline over time of the forced expiratory volume in 1 second (FEV1)8-10 and the
diffusing capacity of carbon monoxide (DLCO) are both considered as biomarkers of AATD
lung disease. While highly variable,11 DLCO measurements correlate with pathology
measurements12 and CT emphysema findings13 such as the relative area of the CT density
histogram ≤ -950 Hounsfield units (RA950).14

More recently, pulmonary imaging

biomarkers that exploit the diffusive motion of inhaled polarized gases such as 3He15 and
129

Xe16 have been measured in patients with emphysema17 using diffusion-weighted MRI

pulse sequences.
In particular, the 3He MRI apparent diffusion coefficient (ADC) was shown to reflect
emphysema.15,18 Multiple b-value diffusion-weighted lung MRI17 also provides estimates
of airway space geometry,17,19 based on the heterogeneous gas displacement in the terminal
airways that are assumed to be cylindrical in shape.20

Such non-invasive MRI

morphometry estimates17 provide a way to bypass or obviate the necessity for pathological
analyses21-24 and may offer crucial information about lung disease progression, as well as
treatment response. Previous MRI studies in AATD patients25-28 showed there was no
statistical difference in ADC values after two-years of follow-up26 but unfortunately, no
morphometry data were acquired. MRI morphometry modelling approaches were recently
evaluated in COPD and AATD patients,29 but this work did not evaluate clinical and other
regional biomarkers. This is important because for AATD patients, emphysematous tissue
destruction ensues early in life and panlobular emphysema is often severe by middle-age.
Therefore, the aim of this study was to evaluate AATD patients using multiple b-value
diffusion-weighted MRI as well as pulmonary function and CT measurements of
emphysema. We hypothesized that MRI measurements would be highly sensitive to
airspace enlargement which would be significantly worse in AATD patients as compared
to clinically similar ex-smokers with COPD.
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Materials and Methods
2.2.1

Study Volunteers and Design

All participants provided written informed consent to a study protocol approved by a local
research ethics board and Health Canada. Patients aged 40-90 years of age with a diagnosis
of AATD and ex-smokers with COPD, >10 pack-years smoking history and CT evidence
of emphysema were recruited from a tertiary care centre and evaluated using spirometry,
plethysmography, thoracic imaging, the St. George’s Respiratory Questionnaire (SGRQ)
and 6-minute walk test (6MWT) during a single two- hour visit. CT evidence of
emphysema was defined as an RA950 ≥ 6.8% as previously described.30 Older neversmokers were also enrolled aged 60-80 years, <0.5 pack-years and no history of chronic
lung disease or uncontrolled cardiovascular disease and completed all study measurements
except for the SGRQ and 6MWT.

2.2.2

Spirometry, Plethysmography, SGRQ and 6MWT

Spirometry measurements were acquired according to the American Thoracic Society
(ATS) guidelines31 using a whole body system (MedGraphics Corporation, St Paul,
Minnesota, USA). Body plethysmography was also performed for the measurement of
lung volumes and DLCO was measured using the attached gas analyzer. The SGRQ32 was
used to establish overall quality of life and the 6MWT33 was used to measure exercise
capacity.

2.2.3

Image Acquisition

MRI was performed on a whole body 3T system (MR750 Discovery, GEHC, Milwaukee,
WI) with broadband imaging capability.34 3He MRI employed a whole body gradient set
with maximum gradient amplitude of 50mT/m and a single-channel, rigid elliptical
transmit/receive chest coil (RAPID Biomedical GmbH, Wuerzburg, Germany). The basis
frequency of the coil was 97.3 MHz and excitation power was 3 kW using an AMT 3T90
RF power amplifier (GEHC). Subjects were positioned supine in the scanner for both 1H
and 3He MRI and instructed by a pulmonary function technologist to inhale a 1L gas
mixture of 3He/N2 (20% 3He by volume) from functional residual capacity (FRC), ensuring
37

a self-consistent lung volume of FRC+1L, with image acquisition performed under breathhold conditions as previously described.34 3He gas was polarized to 30-40% polarization
using a spin-exchange optical polarizer (Polarean Inc, Durham, NC). Diffusion-weighted
3

He MRI data were acquired using a multi-slice interleaved 2D gradient echo diffusion-

weighted sequence with a matrix size of 128x80, for seven 30mm coronal slices (900μs
selective RF pulse, flip angle θ = 4°, TE = 3.9ms, TR=5.6ms, bandwidth=62.5kHz, inplane resolution = 3.125x3.125 mm2, b=0, 1.6, 3.2, 4.8, 6.4 s/cm2); the diffusionsensitization gradient pulse ramp up/down time was 500μs with a diffusion time of 1460μs.
The potential for image artifacts associated with RF pulse “history”35 was addressed by
using an optimal constant flip angle (4 degrees).36 A diffusion-sensitizing, gradient-step,
k-space acquisition scheme starting at the maximum b-value was used to ensure that
maximum MR signal was acquired for diffusion-weighted images at greater b-values. All
five b-value images were acquired during a single 15s breath-hold.
Thoracic CT was acquired on a 64-slice Lightspeed VCT scanner (General Electric Health
Care, Milwaukee, Wisconsin) (64 × 0.625 mm, 120 kVp, 100 effective mA, tube rotation
time=500 msec, and a pitch=1.0). A single spiral acquisition was performed with subjects
in the supine position and at inspiration breath-hold after inhalation of a 1.0L N2 bag from
FRC (NS, AATD1, 6-8) or at full inspiration (COPD, AATD2-5). CT Images were
reconstructed using a slice thickness of 1.25 mm with a standard convolution kernel. The
total effective dose for an average participant was 1.8 mSv according to manufacturer
settings and Imaging Performance Assessment of CT (ImPACT) CT patient dosimetry
calculator based on software from the Health Protection Agency of the United Kingdom
(NRPB-SR250).

2.2.4

Image Analysis

To measure MRI ventilation defect percent (VDP), we used semi-automated segmentation
software (MATLAB R2014b; MathWorks, Natick, Mass) as previously described,37
utilizing an independently acquired image without diffusion weighting.

3

He MRI ADC

maps were generated as described previously38,39 and the Weibel acinar duct model20 was
used to generate morphometry estimates as previously described.17,23,40 Multiple-b-value
38

measurements39 of the

3

He diffusion-attenuated MR signal were used to derive

morphological parameters of the acinar airway, including external radius (R), internal
radius (r), alveolar length (L), depth of alveolar sleeve (h), surface area-to-volume ratio
(S/V) and mean linear intercept (Lm). To model the severe emphysema that accompanies
AATD lung disease, we did not constrain R or r, nor their ratio, unlike previous work in
elderly never-smokers and COPD patients.39 The cylindrical model was used based on
previous work17,41,42 and based on the fact that in AATD patients, normal lung development
and alveolarization is expected.43 Regional ADC and morphometry measurements were
computed using custom-built software generated using MATLAB software whereby the
carina was identified in the b = 0 image and used to segment the lung into apical and basal
regions.
CT airway count, RA950, and low attenuating clusters (LAC) with CT density values ≤ 950 HU44 were determined using Pulmonary Workstation 2.0 (VIDA Diagnostics Inc.,
Coralville, IA).

LAC was calculated using the log-log relationship44 between the

cumulative frequency distribution of emphysematous lesions (# of lesions) and cluster size
(size of lesions) according to the power law relationship Y = XLAC (Y = cumulative
frequency distribution, X = size of lesions). Lower LAC values (more negative) are
indicative of smaller, and fewer, clusters of emphysematous lesions whereas greater LAC
values suggest fewer and larger lesions.

Graphically, this is illustrated as spheres

representing the relative size of emphysematous lesions, with larger spheres indicating
larger and connected low attenuating areas. Regional RA950 was generated using the carina
to segment the lung into apical and basal lung regions.

2.2.5

Statistical Analysis

All statistical analyses were performed using IBM SPSS Statistics, Version 24 (IBM,
Armonk, NY, USA). Comparisons between groups were performed using a multivariate
analysis of variance (MANOVA) with post-hoc Tukey honest significant difference test.
Results were considered significant when the probability of making a Type 1 error was <
5% (p < .05).
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Results
Table 1 provides demographic information for the AATD patient subgroup (n=8, 57±7
years), ex-smokers with COPD (n=8, 77±6 years) and never-smokers (n=5, 64±2 years).
There was significantly different FEV1 (p = .007), FEV1/FVC (p < .0001), RV (p = .03)
and DLCO (p < .0001) for AATD patients as compared to never-smokers but there were no
significant differences between AATD and COPD patients except for age (p < .0001) and
SGRQ (p=.01). COPD patients were significantly older and had a significantly better
SGRQ score indicating better quality of life.

Table 2-1: Demographic and pulmonary function measurements
NeverCOPD
AATD
AATDSmoker
Ex-Smoker
NS-COPD NS-AATD
n=8
COPD
n=5
n=8
Female n
5
1
3
Age yr
64 (2)
77 (6)
57 (7)
.001
.2
<.0001
BMI kg/m2
24 (2)
26 (3)
27 (5)
.8
.6
.9
FEV1 %pred
101 (9)
72 (34)
47 (20)
.1
.007
.2
FVC %pred
96 (9)
94 (26)
78 (21)
.9
.4
.4
FEV1/FVC %
80 (1)
52 (11)
47 (12)
<.0001
<.0001
.8
RV %pred
84 (24)
147 (50)
170 (65)*
.1
.03
.7
TLC %pred
97 (13)
110 (15)
129 (37)*
.2
.2
.9
RV/TLC %
35 (6)
50 (11)
51 (13)*
.05
.06
.9
DLCO %pred
95 (14)
55 (16)
44 (19)*
.002
<.0001
.4
6MWD m
ND
380 (88)
385 (80)
ND
ND
.9††
SGRQ
ND
30 (18)
55 (17)
ND
ND
.01††
FEV1=forced expiratory volume in 1 second; %pred=percent predicted; FVC=forced vital
capacity; RV=residual volume; TLC=total lung capacity; DLCO=diffusing capacity of the
lungs for carbon monoxide; 6MWD=six-minute walk distance; SGRQ=St. George’s
Respiratory Questionnaire total score. MANOVA between groups with post-hoc Tukey
HSD for multiple comparisons. ††Unpaired t-test between COPD and AATD; *n=7.
Parameters
(±SD)

Figure 1 shows CT airway trees and coronal centre slice low attenuating cluster maps as
well as coronal centre slice MRI ventilation and ADC maps for representative participants
in each subgroup.

For the two representative never-smokers, there was little or no

evidence of CT low attenuating regions or clusters while MRI ADC maps were
homogeneous with normal ADC values and ventilation maps reflected relatively few, small
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ventilation defects. In the two representative COPD patients, there were numerous CT low
attenuating regions and low attenuating clusters with large ventilation defects and abnormal
ADC values, mainly in the apical lung. In the two representative AATD patients, CT low
attenuating regions and clusters dominated in the lower lobes and this was concomitant
with highly abnormal MRI ADC values (shown in yellow), mainly in the basal lung.

Figure 2-1: Thoracic CT and MRI for Never-smokers, COPD and AATD
Participants
Left panels: CT RA950 maps (yellow pixels corresponding to voxels <-950 Hounsfield
Units) and CT LAC maps; Right panels: 3He static ventilation (Cyan) co-registered with
1
H MRI; 3He MRI apparent diffusion coefficient (ADC) maps. NS-1 is female age 63 years
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with FEV1=109 %pred, DLCO=103 %pred, RA950=0.19 %, ADC=0.25 cm2/s; NS-4 is female
age 64 years with FEV1=108 %pred, DLCO=99 %pred, RA950=0.13 %, ADC=0.29 cm2/s;
COPD-4 is male age 75 years with FEV1=30 %pred, DLCO=31 %pred, RA950=26 %, ADC
=0.50 cm2/s; COPD-6 is male age 84 years with FEV1=52 %pred, DLCO=47 %pred, RA950=24
%, ADC= 0.50 cm2/s; AATD-1 is male age 67 with FEV1=58 %pred, DLCO=50 %pred,
RA950=19 %, ADC=0.57 cm2/s; AATD-5 is male age 50 with FEV1=25 %pred, DLCO=32
%pred, RA950=27 %, ADC=0.47 cm2/s.

Figure 2 shows the qualitative differences in RA950, ADC and Lm maps for representative
never-smokers, AATD and COPD patients. For example, for NS-2 and NS-5, there was
no evidence, based on RA950 or MRI ADC, of airspace enlargement or emphysema.
However, there was a difference in mean Lm for these two never-smokers with lower,
darker voxels for NS-5, a female aged 63 years as compared to NS-2 a female never-smoker
also aged 63 years and the reasons for these differences were not evident. For COPD and
AATD patients, there was CT evidence of emphysema in the upper (COPD) and basal lung
(AATD). ADC and Lm maps also show brighter colours that reflect enlarged airspaces that
in COPD patients predominated in the upper lobes. In AATD-3, there was highly abnormal
Lm, homogeneously distributed throughout the ventilated portions of the lung. For patient
AATD-2, there was very poor basal lung ventilation and therefore no ADC or
morphometry values could be reported from these regions, although CT showed moderate
basal lung emphysema.
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Figure 2-2: Morphometry Maps for Representative Never-smokers, COPD exsmokers and AATD Patients
Left panels:MRI static ventilation (Cyan) co-registered with 1H MRI; CT RA950 maps
(yellow pixels corresponding to voxels <-950 Hounsfield Units). Right panels: 3He MRI
apparent diffusion coefficient (ADC) and mean linear intercept (Lm) maps. NS-5 is female
age 63 years with FEV1=106 %pred, DLCO=80 %pred, RA950=0.19 %, ADC=0.27 cm2/s,
Lm=180 µm; NS-2 is female age 63 years with FEV1=94 %pred, DLCO=113 %pred,
RA950=0.44 %, ADC= 0.28 cm2/s, Lm=240 µm; COPD-5 is female age 72 years with
FEV1=56 %pred, DLCO=59 %pred, RA950= 8 %, ADC = 0.33 cm2/s, Lm=310 µm; COPD-2 is
male age 79 years with FEV1=126 %pred, DLCO= 62 %pred, RA950= 11%, ADC= 0.41 cm2/s,
Lm=540 µm; AATD-2 is male age 57 with FEV1= 37 %pred, DLCO= ND, RA950= 23 %,
ADC= .46 cm2/s, Lm=680 µm; AATD-3 is female age 62 with FEV1=61 %pred, DLCO=21
%pred, RA950= 31%, ADC= 0.67 cm2/s, Lm=1200 µm.
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Table 2 and Figure 3 provide a summary of quantitative imaging measurements for each
subgroup and Table 3 provides all imaging data by participant. As shown in Table 2, AATD
subjects had significantly elevated whole lung ADC (p= .03), basal lung ADC (p=.045) Lm
(p=.001) and diminished S/V (p=.01) as compared to COPD ex-smokers. RA950 was
significantly elevated in the basal portion of the lungs as compared to the apical portion in
AATD subjects only (p = .03). Figure 3 provides box and whisker plots for whole lung
(top panel), apical (middle panel) and basal (bottom panel) RA950, Lm and ADC by
subgroup. In COPD and AATD patients, there was significantly different whole lung,
apical and basal Lm and ADC, but there was no significant difference in whole lung, apical
or basal RA950. Receiver operating curve (ROC) analysis was also performed between the
AATD and COPD subgroups for Lm, (AUC = .95, p = .002), ADC (AUC = .85, p = .02)
and RA950 (AUC = .71, p = .16).
Table 2-2: Pulmonary MRI and CT measurements
Significance of Difference (p)
NeverCOPD
AATD
NSNSAATDSmoker
Ex-Smoker
n=8
COPD
AATD
COPD
n=5
n=8
WL ADC cm2/s
.27 (.02)
.41 (.07)
.51 (.08)
.005
<.0001
.03
Apical ADC cm2/s
.26 (.02)
.42 (.07)
.48 (.07)
.002
<.0001
.3
2
Basal ADC cm /s
.27 (.02)
.41 (.07)
.53 (.11)
.03
<.001
.045
VDP %
2 (1)
23 (13)
28 (16)
.03
.01
.8
WL Lm µm
220 (80)
480 (250)
890 (330)
.04
<.0001
.001
Apical Lm µm
210 (80)
500 (250)
840 (310)
.02
<.0001
.001
Basal Lm µm
220 (80)
480 (230)
950 (310)
.09
<.0001
.001
S/V cm-1
200 (50)
110 (50)
50 (20)
<.0001
<.0001
.01
WL CT RA950 %
0.2 (0.2)
13 (8)
20 (9)
.01
.001
.3
Apical CT RA950 %
0.2 (0.1)
11 (7)
13 (8)
.02
.007
.8
Basal CT RA950 %
.2 (.2)
14 (8)
21 (10)
.02
.001
.2
CT LAC
-2.1 (.4)
-1.7 (.1)
-1.6 (.2)
.1
.01
.4
Airway count
151 (26)
112 (25)
120 (17)
.02
.1
.5
WL=whole lung; VDP=ventilation defect percent; ADC=apparent diffusion coefficient;
R=external airway radius; r=internal airway radius; h=alveolar sheath; Lm=mean linear
intercept; RA950=relative area of the CT density histogram of attenuation values <-950
Hounsfield Units; LAC=low attenuating clusters. MANOVA between groups with posthoc Tukey HSD for multiple comparisons.
Parameters (±SD)
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Figure 2-3: Regional Imaging Biomarkers
Box and Whisker Plots show mean and standard deviation. NS=never-smoker,
COPD=COPD ex-smoker, AATD=alpha-1 antitrypsin deficiency. RA950=relative area of
the CT lung density histogram with attenuation values <-950 HU, Lm=mean linear
intercept, ADC=apparent diffusion coefficient. Group comparisons performed with an
MANOVA and multiple comparisons corrected with a post-hoc Tukey HSD test.
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Table 2-3: MRI and CT Measurements by Participant
Parameter
(±SD)
NS-1
NS-2
NS-3
NS-4
NS-5
All NS
COPD-1
COPD-2
COPD-3
COPD-4
COPD-5
COPD-6
COPD-7
COPD-8
All COPD
AATD-1
AATD-2
AATD-3
AATD-4
AATD-5
AATD-6
AATD-7
AATD-8
All AATD

ADCWL
cm2/s
.25 (.04)
.28 (.04)
.24 (.02)
.29 (.03)
.27 (.03)
.27 (.02)
.36 (.05)
.41 (.05)
.35 (.03)
.50 (.08)
.33 (.04)
.50 (.05)
.39 (.07)
.43 (.06)
.41 (.07)
.57 (.09)
.46 (.08)
.67 (.10)
.53 (.08)
.47 (.12)
.41 (.09)
.44 (.09)
.53 (.04)
.51 (.08)

ADCAp
cm2/s
.25 (.03)
.26 (.03)
.24 (.02)
.29 (.03)
.26 (.02)
.26 (.02)
.36 (.05)
.43 (.04)
.36 (.03)
.54 (.07)
.30 (.04)
.56 (.05)
.43 (.08)
.43 (.06)
.42 (.07)
.51 (.06)
.39 (.07)
.60 (.08)
.52 (.07)
.48 (.10)
.41 (.06)
.48 (.06)
.45 (.03)
.48 (.07)

ADCBa
cm2/s
.25 (.04)
.29 (.04)
.24 (.02)
.29 (.03)
.27 (.03)
.27 (.02)
.35 (.05)
.39 (.05)
.34 (.04)
.48 (.08)
.34 (.04)
.54 (.06)
.39 (.07)
.43 (.06)
.41 (.07)
.60 (.13)
.51 (.10)
.73 (.12)
.56 (.08)
.46 (.12)
.41 (.10)
.39 (.12)
.57 (.05)
.53 (.11)

VDP
%
2
2
2
2
3
2 (1)
16
16
5
45
14
31
30
25
23 (13)
27
53
13
17
49
10
21
37
28 (16)

Lm(wl)
µm
190 (80)
240 (80)
200 (60)
290 (80)
180 (90)
220 (80)
330 (130)
540 (280)
370 (150)
670 (350)
310 (120)
790 (380)
370 (220)
490 (240)
480 (250)
1000 (410)
680 (320)
1200 (360)
1110 (220)
700 (350)
710 (190)
840 (260)
810 (440)
890 (330)

Lm(Ap)
µm
200 (90)
230 (70)
190 (50)
280 (80)
170 (70)
210 (80)
360 (150)
610 (320)
410 (160)
750 (350)
290 (110)
630 (330)
410 (220)
510 (250)
500 (250)
920 (440)
610 (280)
1200 (380)
1070 (220)
700 (360)
720 (190)
950 (240)
520 (270)
840 (310)

Lm(Ba)
µm
180 (70)
250 (90)
200 (60)
300 (80)
180 (100)
220 (80)
290 (110)
470 (200)
330 (120)
630 (340)
320 (130)
960 (350)
360 (210)
480 (230)
480 (230)
1100 (330)
940 (350)
1270 (330)
1140 (210)
700 (340)
710 (190)
780 (240)
960 (430)
950 (310)

RA950
%
0.2
0.4
0.1
0.1
0.2
0.2 (0.2)
8
11
8
26
8
24
14
8
13 (8)
19
23
31
19
27
3
14
22
20 (9)

LAC
-1.6
-2.4
-2.4
-1.6
-2.3
-2.1 (0.4)
-1.9
-1.7
-1.9
-1.7
-1.9
-1.8
-1.6
-1.6
-1.7 (0.1)
-1.4
-1.9
-1.3
-1.5
-1.6
-1.9
-1.4
-1.7
-1.6 (0.2)

SD=standard deviation; ADC=apparent diffusion coefficient; WL=whole lung; Ap=apical lung; Ba=basal lung; VDP=ventilation defect percent; Lm=mean
linear intercept; S/V=surface to volume ratio; RA950=relative area of the CT density histogram with attenuation values < -950 HU; LAC=low attenuating
clusters
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Discussion
For patients with AATD, pulmonary function tests and thoracic CT measurements of
emphysema are typically used to evaluate disease severity, disease progression and
response to therapy. Unfortunately, such measurements are relatively insensitive to small
changes over time and do not fully explain longitudinal changes in symptoms and quality
of life. Therefore, here our objective was to evaluate inhaled-gas MRI biomarkers of
emphysema in AATD patients and compare these with CT and other clinical measurements
of emphysema in elderly never-smokers and COPD patients with smoking-related
emphysema.21,23 We measured MRI and CT biomarkers of emphysema and observed: 1)
abnormal MRI ADC and Lm measurements that were significantly worse in AATD as
compared to COPD patients in whom CT RA950, airway count and other pulmonary
function test measurements were not significantly different, 2) differences in ADC and Lm
in elderly never-smokers with normal CT, reflecting different senile emphysematous
changes, and, 3) highly abnormal basal lung MRI Lm values in AATD patients although
there was no basal lung ventilation in some AATD patients.
As might be expected, in AATD patients, MRI measurements of ventilation (VDP) and
parenchyma microstructure (ADC) were abnormally elevated in the basal lung. Ventilation
defects were prominent in participants AATD-1, AATD-2 and AATD-5 and this was
consistent with the notion that in severe emphysema, the time constants for lung filling
were longer than the MRI acquisition timeframe. Ventilation defects were also spatially
related to regions with abnormal RA950 and this was previously shown in severe COPD.45,46
In particular, in patient AATD-2, there were large ventilation defects, which was coincident
with a highly abnormal SGRQ score of 80. It is important to note that in this patient, FEV1
did not reflect the severity of emphysema, nor symptoms. In contrast, for Subject AATD6, there was imaging evidence of very mild emphysema and this was in agreement with
modestly abnormal SGRQ, 6MWD and DLCO values.
We were surprised to observe that there was no difference in pulmonary function test and
CT biomarkers of emphysema in AATD patients compared to COPD ex-smokers in whom
there were significantly different Lm, S/V and ADC (WL and basal) measurements. This
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may be due to different underlying pathophysiological mechanisms for panlobular
emphysema, common in AATD patients, as compared to centrilobular emphysema more
common in current or previous smokers without AATD. There was no difference in airway
count between the COPD and AATD subgroups. This is somewhat surprising because
airway count has been suggested as a unique biomarker of COPD in smokers and exsmokers and is an independent predictor of BMI, airflow obstruction, dyspnea, and exercise
capacity (BODE) index47 in COPD patients. The airway count result may stem from a small
sample size but we also note that there was a difference between COPD and NS participants
for airway count. This may suggest that similar to ex-smokers with COPD, in AATD
emphysema, terminal airways are also occluded or obliterated so that they cannot be
resolved using CT. To our knowledge this is a novel result. It is also noteworthy that for
AATD patients with greater overall MRI evidence of airspace enlargement, suggestive of
emphysema, there was greater apical lung ADC which supports the notion that as AATD
worsens, both the basal and apical lung are involved. It is important to point out however
that not all AATD patients present with basal-dominant emphysema48 and this was also
observed here in AATD-7, with greater apical as compared to basal ADC and Lm. Elevated
apical Lm and ADC in AATD-7 may be explained by a 43 pack-year smoking history,
although there is no apical-dominant disease in patient AATD-3 (35 pack years) or patient
AATD-8 (30 pack years). Furthermore, the range of Lm and ADC values for NS may be
indicative of different senile emphysematous changes. While NS-1 and NS-5 both have
smaller airspaces as measured by MRI than age matched NS-4 who has airspaces
approximately 50% larger (190µm vs 290µm). The reasons for this difference is not clear,
but differences in unappreciated environmental exposures or other undetermined causes of
accelerated lung aging in these individuals is possible.
While these cross-sectional results provide good evidence of the feasibility of acquiring
MRI biomarkers in AATD patients, they also provide a better understanding of regional
emphysema and the relationship of emphysema with quality of life in these patients. For
example, perhaps because of the small sample size, SGRQ was the only clinical
measurement that was significantly different in COPD and AATD patients. This finding
is consistent with previous work that showed the relationship of modestly diminished DLCO
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with MRI biomarkers in ex-smokers with normal spirometry but abnormal SGRQ and
6MWD.49 The elevated Lm, ADC and S/V measurements in AATD patients here also
revealed the sensitivity of MRI biomarkers to subtle differences in airspace enlargement
even in the absence of CT measurement differences. Our results suggest that ADC may
better distinguish airspace enlargement observed in NS participants and COPD participants
while Lm may better distinguish between emphysematous lesions in COPD and AATD
patients. We note that previous work50 reported a similar finding for ADC and Lm in exsmokers with and without emphysema using ROC analysis with AUC = .9 (p=.002) for
ADC, and .91 (p=.02) for Lm, respectively. Taken together, these data suggest that MRIderived Lm captures subtle differences between panlobular (AATD) and centrilobular
(COPD) emphysema. We think the sensitivity of MRI can play an important role in
measuring disease progression in longitudinal studies or response to therapy in clinical
trials with small sample sizes, such as evaluated here. Similar to CT biomarkers of
emphysema, MRI biomarkers of airspace enlargement may play an important role in
measuring emphysema in AATD patients undergoing augmentation therapy which is
especially important given the high cost of treatment.
We must acknowledge a number of study limitations and caveats. It is important to note
that a shortcoming of inhaled gas MRI is the reliance of measurements on lung regions that
are well-ventilated. In other words, where there are ventilation defects, no values can be
reported; this generates a bias towards normal values from ventilated lung (in this case,
apical lung). Furthermore, for longitudinal evaluation it is important to ensure that lung
inflation levels is consistent between scans, such as in the RAPID trial4, and this would
certainly help with reproducibility and measurement precision. It is also important to note
that diffusion-weighted MRI reproducibility was previously evaluated by three different
groups including the measurement of precision of ADC values (28, 51, 52) and Lm values
(53). These previous results provided a strong foundation for our approach and for future
longitudinal studies. These factors are important to consider if the techniques evaluated
here are to be used clinically to monitor disease progression in AATD patients over time
and those undergoing augmentation therapy.

Using CT emphysema measurements,

augmentation therapy has been shown to slow the rate of lung tissue density loss and we
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expect that MRI biomarker sensitivity can also be exploited for longitudinal evaluations of
this patient population. We also note that for one participant who was severely impaired,
plethysmography measurements and the 6MWT could not be undertaken; this is certainly
something worth considering for longitudinal studies in AATD patients. It is important to
recognize that we used a cylindrical airway geometry model to estimate MRI Lm which
may not be appropriate in the case of very severe emphysema. Recent work examined the
use of three different emphysema modelling approaches and showed good agreement
between the cylindrical model and another model which made no geometrical
assumptions.29 This and the fact that we did not constrain internal acinar duct radial
parameters suggests that the comparisons made here between COPD and AATD patients
are physiologically relevant. In addition to this, these results are in agreement with recent
morphomic measurements,23 taken at 1.5T, using histology and diffusion-weighted MRI
which measured S/V ratios of approximately 250 cm-1 for healthy controls, 100-140 cm-1
for mild emphysema and 50-55 cm-1 for severe emphysema. These findings are in good
agreement with S/V values measured here in never-smoker (S/V=200±50 cm-1), COPD
(S/V=110±50 cm-1) and AATD subjects (S/V=50±20 cm-1). We should also underscore
the age difference between the study groups which is a limitation of the study because it
was previously established54 that MRI ADC and Lm values are age-dependent values.
Importantly, the AATD participants we evaluated were significantly younger than the
COPD patients, even though lung disease severity based on imaging biomarkers was
greater. This suggests that the elevated ADC and Lm values in the AATD patients were
not due to age differences.
An important limitation is the fact that MRI was performed at FRC+1L in all participants
(i.e., the lung inflation volume was not normalized across subjects). This is important
because lung inflation volume, alveolar inflation and ADC/morphometry values are
related. In our study, MRI was performed at FRC+1L in all participants, with coaching by
a pulmonary function technologist, to ensure that lung volumes were reproducible within
and between participants. This lung volume has been used extensively in the past which
allows for comparison with previous studies and this is, in our experience a relatively
straightforward maneuver for patients with respiratory disease. We note however, that for
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NS-2 and NS-5, the FRC+1L volume was very similar (FRC+1L = 3.8±0.2L) and there
was no significant correlation between Lm and TLC (p=.7) and Lm and FRC+1L (p=.9).
This present study builds upon previous MRI studies in AATD patients25-28 that evaluated
ADC measurements and their changes over relatively short periods of time. Previous work
in COPD patients50 and healthy volunteers39,51 provides a foundation for the current study
that extends the two b-value ADC approach with a single breath whole lung multiple bvalue morphometry approach.29 MRI provides similar and complementary information to
CT with the advantage of being free of ionizing radiation, which is important for AATD
patients who are diagnosed at relatively young ages. These patients have the opportunity
to undergo augmentation therapy; MRI biomarkers that provide sensitive measurements of
airspace enlargement can be considered for these treatment studies and longitudinal
evaluations. MRI also offers novel structure-function biomarkers including measurements
of parenchyma microstructure that correlate with histological samples.21,23,24 Moreover, as
we transition to inhaled 129Xe gas as contrast,16 it is important to note that dissolved-phase
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Xe MRI may be employed to simultaneously estimate ventilation, perfusion 52 and

surrogate measurements of DLCO.53 This information may be very helpful in studies that
evaluate augmentation therapy and other AATD treatments for which direct evidence of
efficacy3,4 has been difficult to ascertain.
In summary, MRI biomarkers of emphysema were significantly different in AATD
subjects as compared to age-matched never-smokers and older ex-smokers with smokingrelated emphysema. Importantly, the significantly different and abnormal Lm values in
AATD patients, who were not significantly different from COPD patients with respect to
pulmonary function tests and CT emphysema measurements, reveals the sensitivity of MRI
emphysema measurements in AATD patients for whom lifelong monitoring is required.

References
(1)
Laurell C-B, Eriksson S. The electrophoretic α; 1-globulin pattern of serum in α; 1antitrypsin deficiency. Scand J Clin Lab Invest. 1963; 15(2):132-140.
(2)
Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir
Crit Care Med. 2012; 185(3):246-259.
51

(3)
Marciniuk D, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted
testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline.
Can Respir J. 2012; 19(2):109-116.
(4)
Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment
and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, doubleblind, placebo-controlled trial. Lancet. 2015; 386(9991):360-368.
(5)
Crystal RG. Augmentation treatment for alpha1 antitrypsin deficiency. Lancet.
2015; 386(9991):318-320.
(6)
Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of [agr]1antitrypsin deficiency in induced pluripotent stem cells. Nature. 2011; 478(7369):391-394.
(7)
Rashid ST, Lomas DA. Stem cell-based therapy for α(1)-antitrypsin deficiency.
Stem Cell Res Ther. 2012; 3(1):1.
(8)
Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation
therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von
Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997; 10(10):22602263.
(9)
Vreim C, Wu M, Crystal R, et al. Survival and FEV1 decline in individuals with
severe deficiency of alpha (1)-antitrypsin. Am J Respir Crit Care Med. 1998; 158(1):4959.
(10) Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal Follow-up of
Patients With α1-Protease Inhibitor Deficiency Before and During Therapy With IV α1Protease Inhibitor*. Chest. 2001; 119(3):737-744.
(11) Hathaway EH, Tashkin D, Simmons MS. Intraindividual Variability in Serial
Measurements of OLeo and Alveolar Volume over One Year in Eight Healthy Subjects
Using Three Independent Measuring Systems. Am Rev Respir Dis. 1989; 140:1818-1822.
(12) Morrison NJ, Abboud RT, Ramadan F, et al. Comparison of single breath carbon
monoxide diffusing capacity and pressure-volume curves in detecting emphysema. Am
Rev Respir Dis. 1989; 139(5):1179-1187.
(13) Gould GA, Redpath AT, Ryan M, et al. Lung CT density correlates with
measurements of airflow limitation and the diffusing capacity. Eur Respir J. 1991;
4(2):141-146.
(14) Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in alpha1antitrypsin deficiency. Thorax. 2003; 58(12):1020-1026.
(15) Saam BT, Yablonskiy DA, Kodibagkar VD, et al. MR imaging of diffusion of 3He
gas in healthy and diseased lungs. Magn Reson Med. 2000; 44(2):174-179.
52

(16) Kim W, Eidelman DH, Izquierdo JL, Ghezzo H, Saetta MP, Cosio MG.
Centrilobular and panlobular emphysema in smokers. Am Rev Respir Dis. 1991;
144:1385-1390.
(17) Yablonskiy DA, Sukstanskii AL, Leawoods JC, et al. Quantitative in vivo
assessment of lung microstructure at the alveolar level with hyperpolarized 3He diffusion
MRI. Proc Natl Acad Sci U S A. 2002; 99(5):3111-3116.
(18) Kirby M, Ouriadov A, Svenningsen S, et al. Hyperpolarized 3He and 129Xe
magnetic resonance imaging apparent diffusion coefficients: physiological relevance in
older never‐and ex‐smokers. Physiol Rep. 2014; 2(7):e12068.
(19) Chan HF, Stewart NJ, Parra-Robles J, Collier GJ, Wild JM. Whole lung
morphometry with 3D multiple b-value hyperpolarized gas MRI and compressed sensing.
Magn Reson Med. 2016:http://dx.doi.org/10.1002/mrm.26279.
(20) Weibel E. Geometry and Dimensions of Airways of Conductive and Transitory
Zones. Morphometry of the Human Lung: Springer Berlin Heidelberg; 1963; 110-135.
(21) Woods JC, Choong CK, Yablonskiy DA, et al. Hyperpolarized 3He diffusion MRI
and histology in pulmonary emphysema. Magn Reson Med. 2006; 56(6):1293-1300.
(22) Tanoli TS, Woods JC, Conradi MS, et al. In vivo lung morphometry with
hyperpolarized 3He diffusion MRI in canines with induced emphysema: disease
progression and comparison with computed tomography. J Appl Physiol. 2007;
102(1):477-484.
(23) Yablonskiy DA, Sukstanskii AL, Woods JC, et al. Quantification of lung
microstructure with hyperpolarized 3He diffusion MRI. J Appl Physiol. 2009;
107(4):1258-1265.
(24) Thomen RP, Quirk JD, Roach D, et al. Direct comparison of Xe diffusion
measurements with quantitative histology in human lungs. Magn Reson Med.
2016:http://dx.doi.org/10.1002/mrm.26120.
(25) Diaz S, Casselbrant I, Piitulainen E, et al. Progression of Emphysema in a 12-month
Hyperpolarized 3 He-MRI Study: Lacunarity Analysis Provided a More Sensitive Measure
than Standard ADC Analysis1. Acad Radiol. 2009; 16(6):700-707.
(26) Stavngaard T, Søgaard LV, Batz M, Schreiber L, Dirksen A. Progression of
emphysema evaluated by MRI using hyperpolarized 3he (hp 3he) measurements in patients
with alpha-1-antitrypsin (a1at) deficiency compared with CT and lung function tests. Acta
Radiol. 2009; 50(9):1019-1026.
(27) Van Beek E, Dahmen A, Stavngaard T, et al. Hyperpolarised 3He MRI versus
HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J. 2009; 34(6):1311-1321.

53

(28) Diaz S, Casselbrant I, Piitulainen E, et al. Hyperpolarized 3He apparent diffusion
coefficient MRI of the lung: reproducibility and volume dependency in healthy volunteers
and patients with emphysema. J Magn Reson Imaging. 2008; 27(4):763-770.
(29) Ouriadov A, Lessard E, Sheikh K, Parraga G. Pulmonary MRI morphometry
modeling of airspace enlargement in chronic obstructive pulmonary disease and alpha‐1
antitrypsin deficiency. Magn Reson Med. 2017.
(30) Gevenois PA, De Vuyst P, de Maertelaer V, et al. Comparison of computed density
and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med.
1996; 154(1):187-192.
(31) Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur
Respir J. 2005; 26(2):319-338.
(32) Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of
health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am
Rev Respir Dis. 1992; 145(6):1321-1327.
(33)

Enright PL. The six-minute walk test. Respir Care. 2003; 48(8):783-785.

(34) Parraga G, Ouriadov A, Evans A, et al. Hyperpolarized 3He ventilation defects and
apparent diffusion coefficients in chronic obstructive pulmonary disease: preliminary
results at 3.0 Tesla. Invest Radiol. 2007; 42(6):384-391.
(35) Miller G, Altes T, Brookeman J, De Lange E, Mugler Iii J. Hyperpolarized 3He
lung ventilation imaging with B 1-inhomogeneity correction in a single breath-hold scan.
MAGMA. 2004; 16(5):218-226.
(36) Ouriadov AV, Lam WW, Santyr GE. Rapid 3-D mapping of hyperpolarized 3He
spin-lattice relaxation times using variable flip angle gradient echo imaging with
application to alveolar oxygen partial pressure measurement in rat lungs. MAGMA. 2009;
22(5):309-318.
(37) Kirby M, Heydarian M, Svenningsen S, et al. Hyperpolarized 3He magnetic
resonance functional imaging semiautomated segmentation. Acad Radiol. 2012;
19(2):141-152.
(38) Kirby M, Heydarian M, Wheatley A, McCormack DG, Parraga G. Evaluating
bronchodilator effects in chronic obstructive pulmonary disease using diffusion-weighted
hyperpolarized helium-3 magnetic resonance imaging. J Appl Physiol. 2012; 112(4):651657.
(39) Paulin GA, Ouriadov A, Lessard E, Sheikh K, McCormack DG, Parraga G.
Noninvasive quantification of alveolar morphometry in elderly never‐and ex‐smokers.
Physiol Rep. 2015; 3(10):e12583.
54

(40) Sukstanskii AL, Yablonskiy DA. In vivo lung morphometry with hyperpolarized
3He diffusion MRI: theoretical background. J Magn Reson. 2008; 190(2):200-210.
(41) Hajari AJ, Yablonskiy DA, Quirk JD, et al. Imaging alveolar-duct geometry during
expiration via 3He lung morphometry. J Appl Physiol. 2011; 110(5):1448-1454.
(42) Yablonskiy DA, Sukstanskii AL, Conradi MS. Commentary on "The influence of
lung airways branching structure and diffusion time on measurements and models of shortrange 3He gas MR diffusion". J Magn Reson. 2014; 239:139-142.
(43) Needham M, Stockley R. α1-Antitrypsin deficiency• 3: Clinical manifestations and
natural history. Thorax. 2004; 59(5):441-445.
(44) Mishima M, Hirai T, Itoh H, et al. Complexity of terminal airspace geometry
assessed by lung computed tomography in normal subjects and patients with chronic
obstructive pulmonary disease. Proc Natl Acad Sci U S A. 1999; 96(16):8829-8834.
(45) Capaldi DP, Zha N, Guo F, et al. Pulmonary imaging biomarkers of gas trapping
and emphysema in COPD: 3He MR imaging and CT parametric response maps. Radiology.
2016; 279(2):597-608.
(46) Kirby M, Pike D, Coxson HO, McCormack DG, Parraga G. Hyperpolarized 3He
ventilation defects used to predict pulmonary exacerbations in mild to moderate chronic
obstructive pulmonary disease. Radiology. 2014; 273(3):887-896.
(47)

Diaz AA, Valim C, Yamashiro T, et al. Airway count and emphysema assessed by

chest CT imaging predicts clinical outcome in smokers. Chest. 2010; 138(4):880-887.
(48) Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in α1antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med.
2004; 170(11):1172-1178.
(49) Kirby M, Owrangi A, Svenningsen S, et al. On the role of abnormal DLCO in exsmokers without airflow limitation: symptoms, exercise capacity and hyperpolarised
helium-3 MRI. Thorax. 2013:thoraxjnl-2012-203108.
(50) Lessard E, Ouriadov A, Capaldi DP, McCormack DG, Parraga G. Novel
Biomarkers Of Lung Parenchyma Destruction And Emphysema Progression In COPD
Using Inhaled Gas MRI Morphometry. Am J Respir Crit Care Med; 2016; 193:A7526
[Abstract].
(51) Morbach AE, Gast KK, Schmiedeskamp J, et al. Diffusion‐weighted MRI of the
lung with hyperpolarized helium‐3: a study of reproducibility. J Magn Reson Imaging.
2005; 21(6):765-774.

55

(52) Mathew L, Evans A, Ouriadov A, et al. Hyperpolarized 3 He magnetic resonance
imaging of chronic obstructive pulmonary disease: reproducibility at 3.0 Tesla. Acad
Radiol. 2008; 15(10):1298-1311.
(53) Quirk JD, Chang YV, Yablonskiy DA. In vivo lung morphometry with
hyperpolarized (3) He diffusion MRI: reproducibility and the role of diffusion-sensitizing
gradient direction. Magn Reson Med. 2015; 73(3):1252-1257.
(54) Quirk JD, Sukstanskii AL, Woods JC, et al. Experimental evidence of age-related
adaptive changes in human acinar airways. J Appl Physiol. 2016; 120(2):159-165.
(55) Quirk JD, Lutey BA, Gierada DS, et al. In Vivo Detection of Acinar Microstructural
Changes in Early Emphysema with 3He Lung Morphometry. Radiology. 2011;
260(3):866-874.
(56) Kaushik SS, Freeman MS, Cleveland ZI, et al. Probing the regional distribution of
pulmonary gas exchange through single-breath gas-and dissolved-phase 129Xe MR
imaging. J Appl Physiol. 2013; 115(6):850-860.
(57) Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review.
Am J Gastroenterol. 2008; 103(8):2136-2141.

56

3

Chapter 3: Conclusions and Future Directions
Overview and Research Questions

This thesis sought to provide measurements of pulmonary airspace enlargement using
diffusion-weighted MRI in COPD and AATD. This is crucial as quantification of lung
structure can be considered the gold standard in evaluation of response to treatment in
COPD.1 COPD is a disease that has tremendous costs both economically and socially in
Canada2 and worldwide.3

Summary and Conclusions
In this thesis, I examined a sample of patients with AATD. I demonstrated that, by using
a multiple-b value diffusion-weighted MRI approach, I could obtain similar, and
complimentary, information to CT; this finding is important in the case of AATD where
disease begins at a young age making longitudinal evaluation of disease using CT
unattractive due to cumulative dose effects. I compared these patients to age-matched
healthy never-smokers and the AATD subjects were significantly worse as measured by
both CT (LAC and RA950) and 3He diffusion MRI (VDP, ADC and morphometry). In
addition, I compared these AATD patients to a group of ex-smokers with smoking related
emphysema. These groups showed no differences in spirometry, CT measurements,
ventilation measurements or exercise capabilities but the AATD group was statistically
worse in terms of perceived quality of life, whole lung and basal ADC, and morphometry
values (whole lung, apical and basal). These results showed that using a small sample
population it is possible to elucidate differences in disease severity by using diffusionweighted MRI. Ultimately, this approach may provide a method of performing smaller
clinical trials examining treatment efficacy in AATD drug development.
In summary, I have 1) examined a patient population who would greatly benefit from
inhaled noble-gas morphometry as a sensitive measurement of disease severity, 2)
demonstrated that whole lung multiple b-value measurements of airspace enlargement are
feasible in this population and 3) demonstrated that this technique can differentiate between
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smoking-related disease and AATD-related disease even in the absence of spirometry or
CT differences.

Limitations
Study specific limitations are discussed in detail in Chapter 2 but the most important
limitations from Chapter 2 and a few major limitations will be discussed in more detail
here.
In Chapter 2 we explored a small sample of AATD patients (n=8) and observed
significantly elevated morphometry values of airspace enlargement. These are elevated as
compared to COPD ex-smokers and age-matched elderly never-smokers. The AATD
subjects showed no difference between the COPD ex-smokers as visualized using CT or
using standard clinical airflow measurements.
Outside of the study specific limitations, there exist limitations inherent to the inhaled
noble-gas morphometry method.

Inhaled noble-gas morphometry measurements are

inherently reliant on gas dispersion throughout the lungs. Essentially, in regions of
ventilation defect, morphometry measurements cannot be acquired. When reporting a
whole lung mean value, this will skew the measurement towards the healthy lung tissue
(regions which are ventilated). Furthermore, this excludes fractions of the lung for
quantitative evaluation, and unfortunately non-ventilated regions cannot distinguish
between emphysematous destruction, mucus clogged airways or other reasons for lack of
ventilation.
Another major limitation of the ADC technique is the intrinsic variation in ADC
measurements that depend on gradient timing parameters. The temporal profile of the
applied bipolar diffusion gradients affects the ADC measurement and as such it is
important to keep this consistent between scans.4,5 Furthermore there is the effect of field
strength on ADC measurements.4

Briefly, in previous work the authors observed

significantly elevated ADC measurements obtained in the same subjects (n=5, healthy
volunteers) at 3T versus 1.5T.

The authors concluded this difference was due to

susceptibility-induced field inhomogeneities. Although, these differences could be
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accounted for by differences in scanner manufacturers (Philips 3T and GE 1.5T).
However, this is still important to keep in mind when comparing measurements across
centres as a difference in obtained ADC may be due to a difference in field strength or
possibly scanner manufacturer. Other factors, such as the spatial profile of the magnetic
field, surface relaxation and surface permeability, also have an effect on the ADC
measured.5
Perhaps the most important limitation of this thesis work is the availability and cost of 3He
and limited access to polarization equipment. This can be partially resolved through
transition to

129

Xe which is more cost effective and naturally abundant. However, until

recently similar levels of polarization could not be achieved with
achieved with 3He.

129

129

Xe as could be

Xe still needs to be polarized prior to use but can reach required

polarization much quicker (~45 minutes) versus 3He (~18 hours) which makes it attractive
for performing serial scans in a single day. However,

129

Xe that has been polarized and

prepared for administration must be used as it now resides outside of the gas cell.

3

He

however does not exit the gas cell until immediately before administration meaning in the
event of scan cancelation or failures up until the moment of administration 3He can still be
recovered and used later whereas 129Xe will be wasted, or at best needs to be recycled.

Future Directions
3.4.1

Overcoming Issues Related to Gas Dispersion

A method of overcoming gas dispersion issues with regards to measuring tissue
microstructure has been explored using modelled Carr-Purcell-Meiboom-Gill (CPMG)
inter-echo time R2 dispersion6 unfortunately this method has yet to transition into in vivo
measurements. Briefly, in this work the authors tested an in silico model of alveoli as
spherical airspaces and derived equations for the relaxation rate R2, the transverse
relaxation rate. They tested their model against deflated rat lungs and demonstrated good
agreement between the mean alveolar radius as measured using this technique (31.5 ± 13
µm) and literature (34 µm).
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3.4.2

Accelerated Imaging

Diffusion-weighted MRI with multiple-b values (5 values) may require as much as 16
seconds acquiring 7 slices. With parallel imaging or compressed sensing, the scan speed
can be greatly increased and the possibility of greater number of slices (>14) can be
achieved. With this there would no longer be a requirement of taking a separate static
ventilation scan to obtain VDP measurements. This would in theory halve the required
volume of gas used to obtain a full set of information that MRI can provide (VDP, ADC,
morphometry). This is especially important both in a clinical setting and a research setting
as the cost of 3He continues to rise due to its natural scarcity. Another possible benefit
would be towards isotropic voxel sizes. Currently 3.125x3.125x30 mm3 are common for
diffusion-weighted scans, and 3.125x3.125x15 mm3 are common for static ventilation
scans. With a large increase in scan speed, smaller voxels would be possible. Preliminary
work has been done with acceleration factors up to x10 with only some lost details as
compared to no acceleration.7
Implementation of parallel imaging, using a multi-channel receive array, would allow an
increase in scan speed. However, it comes with limitations in reduced FOV and aliasing
artifacts. Using the known spatial information of the coils the resulting images are
“unfolded” and the original image is reconstructed. Preliminary work has been performed8
using generalized autocalibrating partially parallel acquisitions (GRAPPA) and an 8channel receive coil, which demonstrated that lung morphometry can be calculated using
parallel imaging without significant differences in measurements. They conclude that even
though the work was performed using 3He that it could be generalized to

129

Xe. This in

turn makes this technique more clinically translatable.

3.4.3

The Transition to 129Xe

Much of the work in noble-gas lung morphometry has been done using 3He due to its high
gyromagnetic ratio and achievable polarization levels. However, with the inevitable
transition from 3He to 129Xe due to the lower cost and greater natural abundance of 129Xe,
it is important to ensure that methods can also be translated. In our lab9 we have compared
three different acinar duct models relying on 3He diffusion. The cylindrical model used in
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this thesis already has a theoretical formulation for the use of

129

Xe and can be readily

translated.10 Another geometrical model assuming spherical symmetry was explored
which is based on varying the diffusion time as opposed to b-value during the scan and can
be readily transitioned to use with 129Xe. The third model, the stretched exponential model,
is without geometrical assumptions, nor assumptions regarding gas diffusivity and due to
this would also be translatable to 129Xe. These considerations are important if this method
is to be used to longitudinally evaluate patients with AATD.
Outside of technical challenges, there is still much work to be done identifying potential
biomarkers of disease using diffusion-weighted MRI in the lung.

3.4.4

Functional Diffusion Maps of the Lungs

There has been work in other organs, specifically in the brain examining the change in
ADC measurements in an imaging voxel across periods of time.11 Functional Diffusion
Maps (FDM), are co-registered ADC maps that stratify regions of the brain into three
distinct categories, i.e., regions which have increased ADC, unchanged ADC or decreased
ADC. FDM has been examined as an early marker of biologic outcome and shows promise
as a tool to predict treatment efficacy early in the drug development process.12 Although
much of this work has been performed in analysis of the brain, FDM can be applied in a
similar fashion as a potential lung disease biomarker. To use FDM for lung disease, ADC
images are taken at time points t1 and t2 (t2>t1). These images are registered together using
an affine transformation13 using the b = 0 s/cm2 slice to ensure the highest signal image is
used in the registration. Unlike in traditional brain FDM, an imaging voxel within the lung
can be categorized into one of five categories: 1) increased ADC, 2) decreased ADC, 3) no
change in ADC, 4) lost ventilation (i.e signal void at t2 where there was signal at t1) and 5)
gained ventilation (i.e signal at t2 where there was a signal void at t1). In order to determine
whether a voxel has increased (or decreased) in ADC at t2 versus t1, a threshold (T) must
be determined to categorize a change as significant. A voxel is categorized as no change
in ADC if |ΔADC| < T.

As a first step in determining T, the variability in ADC

measurements must be determined. Previous work14 has examined same-day rescan and
7-day rescan and has demonstrated a coefficient of variation (COV) and mean ADC for
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never-smokers, mild-moderate COPD and severe COPD. Using the COV and mean ADC
for each subgroup, a variability of approximately 0.01 cm2/s applies across all groups. As
a preliminary step, I defined a threshold of T = 0.01 cm2/s as a significant deviation from
the t1 scan. Figure 3-1 shows a sample workflow for analysis of an AATD subject at two
time points.

Figure 3-1: Functional Diffusion Map Workflow
A) Two visit ADC maps are co-registered
B) Functional diffusion map is generated and clustered into 5 distinct non background
regions
C) A plot of V1 vs V2 ADC with points above the red line showing regions of increased
ADC and points below the blue line showing regions of worse ADC. Green line shows
line of identity
In order to evaluate the effect of a landmark based affine transformation and user variability
on these five distinct regions, a single subject was evaluated five times each day for five
days. The coefficient of variation across both same-day and five day variability was
determined to be 1%, indicating little variation between trials, this is important for
implementation of this technique. Future work should be aimed at examining large patient
databases with multi-visit ADC measurements and evaluating relationships between
clinical outcomes and FDM measurements. Although the focus here has been on 2-visit
ADC maps, it would be possible to extend this to n-visit maps and examine the longitudinal
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change in ADC either as a voxel-wise slope or possibly through another method of analysis.
With the focus of this thesis on multiple-b measurements of airspace enlargement, it would
be simple to extend FDM to Lm maps or any other morphometry measurement acquired
using the morphomic technique.

3.4.5

Longitudinal Evaluation of AATD

This thesis examined AATD disease cross-sectionally. To build upon this cross-sectional
evaluation, a longitudinal study evaluating disease progression over longer periods of time
should be performed to examine the change in lung function as measured by standard
clinical tools and by using hyperpolarized noble-gas MRI. A small, preliminary evaluation
of a single AATD subject (AATD-1 from this thesis) was performed over the course of
approximately five years (Figure 3-2).

Figure 3-2: Longitudinal Evaluation of AATD
As shown in Figure 3-2 the subject has lost ventilation over time (primarily in the lower
lobes as to be expected in AATD related disease) and shows an increase in both ADC and
RA950 qualitatively located in the basal portion of the lungs. Although this analysis was
performed only a single subject it provides motivation for larger longitudinal studies in
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AATD, with the possibility of examining subjects with and without augmentation therapy.
In a continuation study currently undergoing in our lab, subjects with AATD are being
recruited and will be scanned longitudinally (1-3 years follow-up) to examine their lung
function decline as measured using both spirometry and imaging techniques such as CT
and hyperpolarized MRI. Furthermore, by acquiring 129Xe images in this population, the
techniques used and information gained from this study will be one step closer to clinical
translation.

Significance and Impact
Alpha-1 antitrypsin deficiency results in early onset chronic obstructive pulmonary disease
and there is no available cure. Current therapies rely on slowing disease progression.
Longitudinal evaluation of this population is done with nonspecific airflow measurements
and frequent CT scans with the burden of ionizing radiation. Clinical trial endpoints
unfortunately still rely on these methods. Hyperpolarized noble-gas diffusion-weighted
MRI, in particular Lm, provides an opportunity to fill the role of a clinical trial endpoint
and provide a measurement of treatment response that is sensitive to both disease
progression and airspace enlargement. Diffusion-weighted MRI combines the ability to
obtain ventilation defect percentage and measurements of tissue microstructure obtainable
within a single breath-hold without the use of ionizing radiation, making it an attractive
clinical trial endpoint to gauge treatment efficacy. Using a smaller sample than currently
used in clinical trials, treatment efficacy can be evaluated quantitatively using multiple-b
diffusion MRI and can impact the time and cost associated with development of novel
treatments for AATD.
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